PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Amand F. Schmidt; Lucy S. Pearce; John T. Wilkins; John P. Overington; Aroon Hingorani; Juan Pablo Casas

doi:10.1002/14651858.CD011748

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Amand F. Schmidt, Lucy S. Pearce, John T. Wilkins, John P. Overington, Aroon Hingorani, Juan Pablo Casas^*

^*Corresponding author for this work

Julius Center, dept. Epidemiology & Health Economics

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: Primary To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9MABs on lipid parameters and CVD risk. Secondary To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.

Original language	English
Article number	CD011748
Journal	Cochrane Database of Systematic Reviews
Volume	2015
Issue number	6
DOIs	https://doi.org/10.1002/14651858.CD011748
Publication status	Published - 1 Jan 2015

Access to Document

10.1002/14651858.CD011748

Cite this

@article{c6474550e28c4a0da503ff98ab3002da,

title = "PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease",

abstract = "This is the protocol for a review and there is no abstract. The objectives are as follows: Primary To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9MABs on lipid parameters and CVD risk. Secondary To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.",

author = "Schmidt, \{Amand F.\} and Pearce, \{Lucy S.\} and Wilkins, \{John T.\} and Overington, \{John P.\} and Aroon Hingorani and Casas, \{Juan Pablo\}",

year = "2015",

month = jan,

day = "1",

doi = "10.1002/14651858.CD011748",

language = "English",

volume = "2015",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

publisher = "John Wiley \& Sons Inc.",

number = "6",

}

TY - JOUR

T1 - PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

AU - Schmidt, Amand F.

AU - Pearce, Lucy S.

AU - Wilkins, John T.

AU - Overington, John P.

AU - Hingorani, Aroon

AU - Casas, Juan Pablo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: Primary To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9MABs on lipid parameters and CVD risk. Secondary To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.

AB - This is the protocol for a review and there is no abstract. The objectives are as follows: Primary To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9MABs on lipid parameters and CVD risk. Secondary To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.

UR - https://www.scopus.com/pages/publications/85009876004

U2 - 10.1002/14651858.CD011748

DO - 10.1002/14651858.CD011748

M3 - Article

AN - SCOPUS:85009876004

SN - 1469-493X

VL - 2015

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 6

M1 - CD011748

ER -

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Abstract

Access to Document

Other files and links

Fingerprint

Cite this